The global Human Interleukin-2 for Injection market size was valued at US$ 48.2 million in 2024 and is forecast to a readjusted size of USD 64.9 million by 2031 with a CAGR of 4.4% during review period.
Interleukin-2 is ia type of medication called a biologic response modifier. It is a type of protein called a cytokine that works to increase the production and function of some parts of your body"s immune system.
Human Interleukin-2 (IL-2) is a vital immunoregulatory protein used in the treatment of various cancers and immune-related diseases. The market is substantial and continuously expanding, benefiting from the growing population of cancer patients and the widespread application of immunotherapy. Sales are consistently rising, especially in novel immunotherapy fields like CAR-T cell therapy. Specific uses include the treatment of malignancies such as malignant melanoma, renal cell carcinoma, and advanced metastatic colorectal cancer. The future development prospects are promising, with anticipated approvals for more indications and treatment modalities driving continued market growth.
This report is a detailed and comprehensive analysis for global Human Interleukin-2 for Injection market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Human Interleukin-2 for Injection market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Human Interleukin-2 for Injection market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Human Interleukin-2 for Injection market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Human Interleukin-2 for Injection market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Human Interleukin-2 for Injection
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Human Interleukin-2 for Injection market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Clinigen, 3SBio, Beijing Four Rings Biopharmaceutical, Jiangsu Kingsley Pharmaceutical, Beijing Yuance Pharmaceutical, Beijing SL Pharm, Shanghai Huaxin Biotechnology, Changchun Institute Of Biological Products, Shandong Quangang Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Human Interleukin-2 for Injection market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
50000 IU
100000 IU
200000 IU
500000 IU
1 Million IU
麻豆原创 segment by Application
Hospital
Pharmacy
Major players covered
Clinigen
3SBio
Beijing Four Rings Biopharmaceutical
Jiangsu Kingsley Pharmaceutical
Beijing Yuance Pharmaceutical
Beijing SL Pharm
Shanghai Huaxin Biotechnology
Changchun Institute Of Biological Products
Shandong Quangang Pharmaceutical
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Human Interleukin-2 for Injection product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Human Interleukin-2 for Injection, with price, sales quantity, revenue, and global market share of Human Interleukin-2 for Injection from 2020 to 2025.
Chapter 3, the Human Interleukin-2 for Injection competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Human Interleukin-2 for Injection breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Human Interleukin-2 for Injection market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Human Interleukin-2 for Injection.
Chapter 14 and 15, to describe Human Interleukin-2 for Injection sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Human Interleukin-2 for Injection Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 50000 IU
1.3.3 100000 IU
1.3.4 200000 IU
1.3.5 500000 IU
1.3.6 1 Million IU
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Human Interleukin-2 for Injection Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Pharmacy
1.5 Global Human Interleukin-2 for Injection 麻豆原创 Size & Forecast
1.5.1 Global Human Interleukin-2 for Injection Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Human Interleukin-2 for Injection Sales Quantity (2020-2031)
1.5.3 Global Human Interleukin-2 for Injection Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Clinigen
2.1.1 Clinigen Details
2.1.2 Clinigen Major Business
2.1.3 Clinigen Human Interleukin-2 for Injection Product and Services
2.1.4 Clinigen Human Interleukin-2 for Injection Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Clinigen Recent Developments/Updates
2.2 3SBio
2.2.1 3SBio Details
2.2.2 3SBio Major Business
2.2.3 3SBio Human Interleukin-2 for Injection Product and Services
2.2.4 3SBio Human Interleukin-2 for Injection Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 3SBio Recent Developments/Updates
2.3 Beijing Four Rings Biopharmaceutical
2.3.1 Beijing Four Rings Biopharmaceutical Details
2.3.2 Beijing Four Rings Biopharmaceutical Major Business
2.3.3 Beijing Four Rings Biopharmaceutical Human Interleukin-2 for Injection Product and Services
2.3.4 Beijing Four Rings Biopharmaceutical Human Interleukin-2 for Injection Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Beijing Four Rings Biopharmaceutical Recent Developments/Updates
2.4 Jiangsu Kingsley Pharmaceutical
2.4.1 Jiangsu Kingsley Pharmaceutical Details
2.4.2 Jiangsu Kingsley Pharmaceutical Major Business
2.4.3 Jiangsu Kingsley Pharmaceutical Human Interleukin-2 for Injection Product and Services
2.4.4 Jiangsu Kingsley Pharmaceutical Human Interleukin-2 for Injection Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Jiangsu Kingsley Pharmaceutical Recent Developments/Updates
2.5 Beijing Yuance Pharmaceutical
2.5.1 Beijing Yuance Pharmaceutical Details
2.5.2 Beijing Yuance Pharmaceutical Major Business
2.5.3 Beijing Yuance Pharmaceutical Human Interleukin-2 for Injection Product and Services
2.5.4 Beijing Yuance Pharmaceutical Human Interleukin-2 for Injection Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Beijing Yuance Pharmaceutical Recent Developments/Updates
2.6 Beijing SL Pharm
2.6.1 Beijing SL Pharm Details
2.6.2 Beijing SL Pharm Major Business
2.6.3 Beijing SL Pharm Human Interleukin-2 for Injection Product and Services
2.6.4 Beijing SL Pharm Human Interleukin-2 for Injection Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Beijing SL Pharm Recent Developments/Updates
2.7 Shanghai Huaxin Biotechnology
2.7.1 Shanghai Huaxin Biotechnology Details
2.7.2 Shanghai Huaxin Biotechnology Major Business
2.7.3 Shanghai Huaxin Biotechnology Human Interleukin-2 for Injection Product and Services
2.7.4 Shanghai Huaxin Biotechnology Human Interleukin-2 for Injection Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Shanghai Huaxin Biotechnology Recent Developments/Updates
2.8 Changchun Institute Of Biological Products
2.8.1 Changchun Institute Of Biological Products Details
2.8.2 Changchun Institute Of Biological Products Major Business
2.8.3 Changchun Institute Of Biological Products Human Interleukin-2 for Injection Product and Services
2.8.4 Changchun Institute Of Biological Products Human Interleukin-2 for Injection Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Changchun Institute Of Biological Products Recent Developments/Updates
2.9 Shandong Quangang Pharmaceutical
2.9.1 Shandong Quangang Pharmaceutical Details
2.9.2 Shandong Quangang Pharmaceutical Major Business
2.9.3 Shandong Quangang Pharmaceutical Human Interleukin-2 for Injection Product and Services
2.9.4 Shandong Quangang Pharmaceutical Human Interleukin-2 for Injection Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Shandong Quangang Pharmaceutical Recent Developments/Updates
3 Competitive Environment: Human Interleukin-2 for Injection by Manufacturer
3.1 Global Human Interleukin-2 for Injection Sales Quantity by Manufacturer (2020-2025)
3.2 Global Human Interleukin-2 for Injection Revenue by Manufacturer (2020-2025)
3.3 Global Human Interleukin-2 for Injection Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Human Interleukin-2 for Injection by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Human Interleukin-2 for Injection Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Human Interleukin-2 for Injection Manufacturer 麻豆原创 Share in 2024
3.5 Human Interleukin-2 for Injection 麻豆原创: Overall Company Footprint Analysis
3.5.1 Human Interleukin-2 for Injection 麻豆原创: Region Footprint
3.5.2 Human Interleukin-2 for Injection 麻豆原创: Company Product Type Footprint
3.5.3 Human Interleukin-2 for Injection 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Human Interleukin-2 for Injection 麻豆原创 Size by Region
4.1.1 Global Human Interleukin-2 for Injection Sales Quantity by Region (2020-2031)
4.1.2 Global Human Interleukin-2 for Injection Consumption Value by Region (2020-2031)
4.1.3 Global Human Interleukin-2 for Injection Average Price by Region (2020-2031)
4.2 North America Human Interleukin-2 for Injection Consumption Value (2020-2031)
4.3 Europe Human Interleukin-2 for Injection Consumption Value (2020-2031)
4.4 Asia-Pacific Human Interleukin-2 for Injection Consumption Value (2020-2031)
4.5 South America Human Interleukin-2 for Injection Consumption Value (2020-2031)
4.6 Middle East & Africa Human Interleukin-2 for Injection Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Human Interleukin-2 for Injection Sales Quantity by Type (2020-2031)
5.2 Global Human Interleukin-2 for Injection Consumption Value by Type (2020-2031)
5.3 Global Human Interleukin-2 for Injection Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Human Interleukin-2 for Injection Sales Quantity by Application (2020-2031)
6.2 Global Human Interleukin-2 for Injection Consumption Value by Application (2020-2031)
6.3 Global Human Interleukin-2 for Injection Average Price by Application (2020-2031)
7 North America
7.1 North America Human Interleukin-2 for Injection Sales Quantity by Type (2020-2031)
7.2 North America Human Interleukin-2 for Injection Sales Quantity by Application (2020-2031)
7.3 North America Human Interleukin-2 for Injection 麻豆原创 Size by Country
7.3.1 North America Human Interleukin-2 for Injection Sales Quantity by Country (2020-2031)
7.3.2 North America Human Interleukin-2 for Injection Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Human Interleukin-2 for Injection Sales Quantity by Type (2020-2031)
8.2 Europe Human Interleukin-2 for Injection Sales Quantity by Application (2020-2031)
8.3 Europe Human Interleukin-2 for Injection 麻豆原创 Size by Country
8.3.1 Europe Human Interleukin-2 for Injection Sales Quantity by Country (2020-2031)
8.3.2 Europe Human Interleukin-2 for Injection Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Human Interleukin-2 for Injection Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Human Interleukin-2 for Injection Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Human Interleukin-2 for Injection 麻豆原创 Size by Region
9.3.1 Asia-Pacific Human Interleukin-2 for Injection Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Human Interleukin-2 for Injection Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Human Interleukin-2 for Injection Sales Quantity by Type (2020-2031)
10.2 South America Human Interleukin-2 for Injection Sales Quantity by Application (2020-2031)
10.3 South America Human Interleukin-2 for Injection 麻豆原创 Size by Country
10.3.1 South America Human Interleukin-2 for Injection Sales Quantity by Country (2020-2031)
10.3.2 South America Human Interleukin-2 for Injection Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Human Interleukin-2 for Injection Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Human Interleukin-2 for Injection Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Human Interleukin-2 for Injection 麻豆原创 Size by Country
11.3.1 Middle East & Africa Human Interleukin-2 for Injection Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Human Interleukin-2 for Injection Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Human Interleukin-2 for Injection 麻豆原创 Drivers
12.2 Human Interleukin-2 for Injection 麻豆原创 Restraints
12.3 Human Interleukin-2 for Injection Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Human Interleukin-2 for Injection and Key Manufacturers
13.2 Manufacturing Costs Percentage of Human Interleukin-2 for Injection
13.3 Human Interleukin-2 for Injection Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Human Interleukin-2 for Injection Typical Distributors
14.3 Human Interleukin-2 for Injection Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Clinigen
3SBio
Beijing Four Rings Biopharmaceutical
Jiangsu Kingsley Pharmaceutical
Beijing Yuance Pharmaceutical
Beijing SL Pharm
Shanghai Huaxin Biotechnology
Changchun Institute Of Biological Products
Shandong Quangang Pharmaceutical
听
听
*If Applicable.
